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Abstract
Background: Transsphenoidal surgery (TSS) remains the treatment of choice for non-functioning pituitary
macroadenomas (NFPMA). The value of measuring tumour volumes before and after surgery, and its influence on
endocrine outcomes and further treatment of the residual or recurrent tumour are unknown.
Methods: Data from patients who underwent endoscopic TSS for a NFPMA (2009–2018) in a UK tertiary centre
were analysed for pre- and post-operative endocrine and surgical outcomes.
Results: Of 173 patients with NFPMA, 159 (61% male) were treatment naïve. At presentation, 76.2% (77/101) had
≥1 pituitary axis deficit. Older age (p = 0.002) was an independent predictor for multiple hormonal deficiencies.
Preoperative tumour volume did not correlate with degree of hypopituitarism. Postoperative tumour volume and
extent of tumour resection were not predictive of new onset hypopituitarism. Hormonal recovery was observed in
16 patients (20.8%) with impaired pituitary function, with the greatest recovery in the hypothalamic-pituitary-
adrenal axis (21.2%, 7/33). A larger residual tumour volume was predictive of adjuvant radiotherapy (3.40 vs. 1.24
cm3, p = 0.005) and likelihood for repeat surgery (5.40 vs. 1.67cm3, p = 0.004).
Conclusion: Pre- and post-operative NFPMA volumes fail to predict the number of pituitary hormone deficits,
however, greater post-operative residual volumes increase the likelihood of further intervention to control tumour
growth.
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Background
Non-functioning pituitary adenomas (NFPA) are benign
tumours that constitute around one-third of all pituitary
neoplasms, have a prevalence of 7–22 cases per 100,000
population [1, 2] and a standardized incidence rate of
1.02–1.08/100,000 [3, 4]. As they do not cause pituitary
hormonal hypersecretion syndromes, the diagnosis is ei-
ther made incidentally during radiological imaging for
other indications or when they are large enough to exert
pressure effects to surrounding tissues, resulting in
headaches and / or visual defects from optic chiasm
compression [5]. Notably, in the majority of patients pi-
tuitary hormone deficits are demonstrable at presenta-
tion. Studies assessing endocrine function in these
individuals using various diagnostic criteria have shown
growth hormone (GH) deficiency to be present in 77–
88% of patients at presentation, gonadotropin (Gn) defi-
ciency in 61–78%, while corticotropin (19–53%) and
thyrotropin (19–43%) deficiencies are noted to a lesser
degree [6–10].
NFPA are categorized as macroadenomas when larger
than 10 mm in diameter. The treatment of choice in pa-
tients with non-functioning pituitary macroadenomas
(NFPMA) is transsphenoidal surgery (TSS), aiming for
preservation or restoration of vision and long-term
tumour control. More recently, the endoscopic endona-
sal technique is emerging as the primary choice for sur-
gical debulking as an alternative to the microscopic
approach [11–13]. Regardless of either technique, sur-
gery should only be performed by an experienced dedi-
cated pituitary surgeon as this enhances success rate and
reduces complications [6]. Nonetheless, hypopituitarism
prevails in a considerable portion of patients following
surgery and is expected to worsen if adjuvant pituitary
radiotherapy is required.
In the present study we analysed results of a consecu-
tive series of patients who underwent TSS for resection
of NFPMA since adoption of the endoscopic approach
in our centre in July 2009. The primary aim was to
examine the predictive value of pre-operative tumour




We performed a retrospective analysis of consecutive
adult patients who underwent endoscopic transsphenoi-
dal resection for non-functioning pituitary adenoma be-
tween 01 July 2009 and 31 August 2018 at Leeds
Teaching Hospitals NHS Trust (LTHT). Only macroade-
nomas were included.
Patients were identified using the neurosurgical data-
base collated at the time of surgery by the pituitary sur-
geons (neurosurgery and ear, nose and throat) within
our institution. LTHT is a dedicated multidisciplinary
centre of pituitary expertise in the North and West
Yorkshire region of the UK, serving a population of 2.9
million [14]. Patients were referred to the neurosurgical
service mainly from the endocrinology department at
LTHT and also directly from various hospitals in the
catchment area (including six peripheral hospitals) after
initial endocrine evaluation. Details concerning thera-
peutic intervention and results of endocrine investiga-
tions were collected from patients’ medical notes and
electronic patient records (PATIENT PATHWAY
MANAGER and the PATHOLOGY RESULTS SERVER).
Data were compiled by trained staff over a four-month
period between December 2018 and March 2019.
Patient episodes were subdivided into those which
were performed in patients who were surgically naïve
(Group A), and those representing second surgery for
their pituitary adenoma (repeat endoscopic TSS, or
endoscopic TSS following previous microscopic TSS /
transcranial tumour resection; Group B). For each pa-
tient, information at baseline, and after surgery were re-
corded – namely at the first post-operative endocrine
evaluation (usually 6 weeks) and at the time of the last
clinic assessment. These included demographic details,
surgical and radiology reports, tumour histology, pre-
operative and post-operative tumour volume, endocrine
assessments as well as the need for radiotherapy and fur-
ther surgery.
Evaluation of pituitary function
Pituitary function testing was performed at baseline and
at 6 weeks postoperatively. The presence of hypopituitar-
ism (partial or complete), number of axes involved, the
presence of diabetes insipidus, and hyperprolactinaemia
were registered.
GH and Hypothalamo–Pituitary–Adrenal (HPA) axes
The insulin tolerance test (ITT) was the preferred
method for assessing the integrity of the GH and HPA
axes. Where the ITT was contraindicated (i.e. history of
epilepsy, increased cardiovascular risk, age > 65 years),
the glucagon stimulation test (GST) was performed [15].
Pituitary investigations were performed at presentation
and 6 weeks postoperatively. Patients who underwent
radiotherapy (RT) underwent a further dynamic pituitary
test in the first year following treatment and annually
afterwards unless GH and ACTH deficiency had previ-
ously been confirmed. Both for the ITT and the GST,
severe GH deficiency was defined as a peak GH response
of less than 3 mcg/l [15]. Patients with incomplete pre-
or post-operative GH dynamic testing were excluded in
the final analysis for endocrine evaluation. GH status at
baseline was not routinely assessed by stimulation test in
the regional peripheral hospitals. Additionally, where
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urgent debulking was necessary (apoplexy, acute visual
deterioration), dynamic GH testing was not prioritised
in the preoperative setting. ACTH deficiency in our la-
boratory was defined by a locally validated peak cortisol
of less than 500 nmol/l for the ITT and less than 450
nmol/l for the GST [15]. Patients with borderline corti-
sol response to the GST (peak cortisol between 400 and
450 nmol/l) were subsequently investigated using the
short Synacthen test (SST), to determine the clinical
need for glucocorticoid replacement therapy [15]. Corti-
sol values at baseline (09:00 h) and 30min following
250 μg of intramuscular cosyntropin (tetracosactide)
were used to define adrenal insufficiency. The cut-off for
an acceptable response was defined as greater than 450
nmol/l, based on local normative data.
Additional anterior pituitary hormones
LH, FSH, TSH, prolactin, IGF-1, free T4, testosterone
in males and oestradiol in females, were measured in
morning serum samples [15]. In males, hypogonado-
trophic hypogonadism was defined by a low serum
testosterone (< 8 nmol/l) in combination with inappro-
priately normal or low gonadotropins (Gn) [15]. In
premenopausal females, Gn deficiency was defined as
the presence of symptoms of oligo- or amenorrhoea,
low oestradiol levels and inappropriately normal or
low LH/FSH [15]. In postmenopausal women, the ab-
sence of elevated Gn concentration (< 30 IU/L) was
indicative of Gn deficiency [15]. Low levels of free
thyroxine (fT4; normal range 10–20 pmol/l) in the
presence of low, normal or mildly elevated TSH (<
6miu/l), in patients without a pre-existing history of
thyroid disease, were deemed diagnostic of thyrotroph
dysfunction [15]. Permanent diabetes insipidus (DI)
was diagnosed as the persistence of hypotonic poly-
uria, responsive to desmopressin (DDAVP) at the 6-
week postoperative assessment; water deprivation tests
were not routinely performed. Multiple hormone defi-
ciencies were defined by deficiency of at least two in-
dividual anterior pituitary hormone axes.
Panhypopituitarism was defined as the co-existence of
GH, Gn, ACTH and TSH deficiencies. Patients lack-
ing laboratory values for a particular axis were ex-
cluded from the analysis of that particular axis.
After the initial postoperative endocrine assessment,
patients were reviewed on an annual basis during
follow-up and subsequent hormone testing was carried
out at the discretion of the clinician. Patients routinely
had an annual pituitary hormone profile to assess the
adequacy of hormone replacement. Dynamic testing of
the GH and HPA axes were performed post-
radiotherapy or during tumour recurrence/ growth as
indicated.
Laboratory assays
GH and IGF-1 were measured using SIEMENS
IMMUNLITE 2000 methodology (GH calibrated against
WHO NIBSC IS 98/574) [15]. Cortisol, prolactin and
oestradiol were measured by immunoassay on the SIEM
ENS ADVIA CENTAUR. LH, FSH, TSH and free T4
were measured by chemiluminescence using SIEMENS
ADVIA CENTAUR and testosterone was measured
using isotope-dilution liquid chromatography–tandem
mass spectrometry [15]. All assays were performed in
the routine clinical biochemistry laboratories within the
Leeds Teaching Hospitals NHS Trust and have been
regularly validated by internal quality control (IQC) and
external quality assessment (EQA) [15].
Imaging study and tumour volume
The radiographic evaluation consisted of 1.5 T magnetic
resonance imaging (MRI) with and without contrast per-
formed pre-operatively, at 3–6months post-surgery and
yearly thereafter for the first 5 years.
Tumour volume was measured using MRI with
BRAINLAB IPLAN NET software pre-operatively and
post-operatively at 3 months after surgery. Gross total
resection (GTR) was achieved when complete macro-
scopic removal of the adenoma had been carried out
(defined as absence of visible tumour residuum on post-
operative MRI as reported by the neuroradiologist);
near-total resection (NTR) when more than 90% of the
tumour was removed; sub-total resection (STR) when 75
to 90% of the tumour was removed; and partial resection
when less than 75% of the tumour was removed [16].
Extent of resection (EOR) was calculated based on volu-
metric analysis of pre-and post-operative contrast-
enhanced MRI according to the formula: [(Preoperative
tumour volume (PTV) – Residual tumour volume) /
PTV] × 100%.
Follow up
All patients had a post-operative MRI scan at 3 months
after TSS. This was followed by annual neurosurveil-
lance imaging for the next 5 years and 2-yearly there-
after, unless patients became symptomatic of headaches
or visual loss which would warrant earlier imaging out-
side the surveillance protocol. Tumour recurrence was
defined by the appearance of visible tumour on pituitary
imaging after GTR had been previously achieved.
Tumour regrowth was defined by enlargement of a
remnant tumour after TSS following review by a dedi-
cated pituitary neuroradiologist. Patients with remnant
tumours or recurrence in proximity to the optic chiasm
had annual visual field assessment as part of monitoring.
Further intervention, either in the form of repeat surgery
or radiotherapy, was considered on a case-by-case basis
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after discussion with neurosurgeons and oncologists in a
multidisciplinary setting.
Statistical analysis
Results are presented as mean and standard deviation,
or median and range for parametric and nonparametric
data respectively [15]. Chi-squared and Fisher exact tests
were used to compare frequencies and proportions of
categorical variables. The Mann–Whitney U-test and
student’s t-tests were used to compare differences be-
tween continuous variables (age, tumour volume, extent
of resection) in patient groups with different endocrine
outcomes (new axis deficit vs. preserved pituitary func-
tion). A multiple linear regression analysis was per-
formed to examine variables contributing to the
development of pituitary hormone deficits. A p-value of
< 0.05 was considered statistically significant for all tests.
The regrowth-free curves were generated by the Kaplan-
Meier method. Statistical analysis was performed using
MICROSOFT EXCEL (Version 16.43) and GRAPHPAD
PRISM 8 [Statistical software, Version 8.4.3 (471)].
Ethical considerations
This study was designed as a clinical service review to
assess current practice, make quality improvements and
improve patient outcomes. Given that it was undertaken
using retrospective de-identified data collected during
the course of routine care by the direct care team as part
of usual practice, no informed consent was requested
from the patients. The study protocol was approved by
the local Research and Innovation department at Leeds
Teaching Hospitals NHS Trust who acknowledged wai-
ver of consent and confirmed that the study did not re-
quire Health Research Authority (HRA) approval and
therefore no NHS Research Ethics Committee (REC) re-
view. Research data for this study was obtained from the
neurosurgical database created and maintained by the
local pituitary surgeons at LTHT (neurosurgeons NP
and AT and ENT surgeons PN and TW) as part of rou-
tine postoperative practice. No administrative permis-
sions were required to access this anonymized data
provided by co-authors NP, AT, PN and TW who
shared ownership rights.
All methods were carried out in accordance with rele-
vant guidelines and regulations for medical research in-
volving human subjects of the Declaration of Helsinki.
Results
Patient characteristics
A total of 173 patients with NFPMA who underwent
endoscopic endonasal TSS were identified (107 males
and 66 females). Of these individuals 159 were treatment
naïve (Group A), and 14 had undergone previous sur-
gery via microscopic TSS or transcranial surgery – 1/14
had received radiotherapy after the first surgery. Of the
treatment naïve patients (Group A) 9/159 went on to
have further surgery during the follow-up period, none
of whom underwent prior radiotherapy. Therefore, data
were available on a total of 23 patients who underwent
endoscopic TSS, having had prior pituitary surgery
(Group B).
Treatment Naïve patients (group a; Table 1)
The most frequent presentation was visual loss (n = 90/
159, 56.6%). Twenty-seven patients (17.0%) were asymp-
tomatic and the diagnosis of a NFPMA was incidental.
Presence of a visual field defect on clinical assessment
(n = 104, 65.6%) was the most common indication for
surgery. The mean patient age at the time of surgery was
59.3 ± 13.3 (range 21–87) years. No significant differ-
ences in the age distribution of patients according to
gender were found. Eight patients (5.0%) presented
acutely, necessitating emergency surgical debulking. Im-
munohistochemical analysis identified most resected tu-
mours to be silent gonadotroph (n = 84, 52.8%)
adenomas. Mean length of follow-up post-TSS was 3.1 ±
2.1 years. Eleven deaths were recorded during the study
period – three patients died within the first year follow-
ing TSS, none of which was directly related to the pituit-
ary surgery.
Endocrine evaluation
The prevalence rates of GH, Gn, ACTH and TSH defi-
ciencies are shown in Table 1. We compared pre- and
post-operative pituitary function only in those patients
who had formal pre- and post-operative assessments.
Forty-eight patients did not have complete dynamic GH
testing either at baseline or after surgery and were ex-
cluded from the final analysis for endocrine evaluation.
Provocative testing of the GH axis was routinely per-
formed only in patients referred directly from the Endo-
crinology Department at Leeds Teaching Hospitals,
except in presentations requiring urgent tumour debulk-
ing. Peripheral hospitals carried out serum IGF-1 mea-
surements, unless patients developed symptoms
suggestive of GH deficiency despite receiving optimal
treatment for other pituitary hormone deficiencies as ne-
cessary. In addition, patients with missing endocrine
data pertaining to gonadal, thyroidal or HPA axes at
baseline and/ or at follow-up (n = 10) were also ex-
cluded. Complete pre- and post-operative pituitary hor-
mone function was available in 101/159 patients when
the database was frozen on 31st March 2019.
At presentation
Twenty-four patients (23.8%) had normal pituitary func-
tion, 41 (40.6%) had 1–2 anterior pituitary axis deficits,
and 36 patients (35.6%) had at least 3-axis deficits of
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Table 1 Characteristics and post-operative outcomes of surgical naïve patients (Group A) undergoing endoscopic TSS
Characteristics Values
N 159
Gender M: 97 (61.0%); F: 62 (39.0%)
Mean age at surgery (years) 59.3 ± 13.3; Range = 21-87 years
Presentation
• Loss of vision 90 (56.6%)
• Incidental (Asymptomatic) 27 (17.0%)
• Symptoms of hypopituitarism 18 (11.3%); (8-Hypogonadism)
• Headaches 13 (8.2%)
• Apoplexy 9 (5.7%)
• CN palsy 2 (1.3%)
Emergency 8 (6- apoplexy, 1-visual loss, 1-CN palsy)
Indication for surgery
• Visual field defect 104 (65.4%)
• Contact with optic chiasm/ suprasellar extension (sight-threatening) 33 (20.8%)
• Apoplexy 9 (5.7%)
• Large tumour volume 6 (3.8%)
• Enlarging tumour on surveillance 4 (2.5%)
• CN involvement 3 (1.9%)
Immunohistochemistry
• Gonadotroph 84 (52.8%)
• Null Cell 52 (32.7%)
• Plurihormonal adenoma 3 (1.9%)
• Silent corticotroph adenoma 8 (5.0%)
• Silent thyrotroph adenoma 1 (0.6%)
• Silent somatotroph adenoma 1 (0.6%)
• Silent lactotroph adenoma 1 (0.6%)
• Hyperplasia 1 (0.6%)
• Other (necrotic, infarcted, normal, no tissue) 8 (5.0%)
Post-surgical outcomesa
Endocrinopathies At diagnosis (n=
101)
Post-operative (n=101)
• Normal pituitary function 24 (23.8%) 20 (19.8%)
• 1-2 anterior pituitary axis deficits 41 (40.6%) 43 (42.6%)
• ≥ 3 anterior pituitary axis deficits 36 (35.6%) 38 (37.6%)
• ADH deficiency 0 2 (2.0%) + 2 transient
DI
Individual pituitary axis At diagnosis (n=
101)
Post-operative (n=101)
• GH deficiency 60 (59.4%) 71 (70.3%)
• LH/ FSH deficiency 55 (54.5%) 56 (55.4%)
• ACTH deficiency 33 (32.7%) 37 (36.6%)
• TSH deficiency 36 (35.6%) 37 (36.6%)
Preserved pituitary function (n=101, total cohort) 60 (59.4%)
Pituitary axis recovery (n=77, excluding 24 patients with normal pituitary function pre-op) 16 (20.8%)
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whom 18 patients, predominantly males (n = 14, 77.7%)
had panhypopituitarism (all 4 anterior axes impaired), as
shown in Table 1. None of the patients had cranial dia-
betes insipidus at diagnosis. The most frequently af-
fected hormonal axis was GH deficiency (n = 61, 60.4%)
followed by LH/ FSH deficiency (n = 55, 54.5%). Table 2
shows the pituitary hormone function in the study popu-
lation at baseline. Older age (coeff 0.26, p = 0.001) was a
significant independent predictive factor for multiple pi-
tuitary hormone deficiencies at presentation. Men dis-
played a higher prevalence of GH deficiency (63.4% vs.
43.5%, p = 0.01). Secondary ACTH and LH/FSH defi-
ciencies were more common in older patients at presen-
tation (63.2 vs. 57.2 years, p = 0.03; 63.5 vs 54.0 years,
p < 0.01).
Post-operative outcomes
Overall 20 patients (19.8%) had normal pituitary func-
tion post-operatively. Pituitary function remained un-
changed postoperatively in 59% (n = 60) of patients. New
axis deterioration was observed in 25 patients after TSS,
corresponding to an overall proportion of 30.1% (25/83)
when excluding the patients who already had all 4
anterior axes impaired pre-operatively (n = 18) and thus
could not have further hormone deficits (Table 1).
Considering the pituitary axes individually, the GH
axis was most susceptible to damage post-operatively.
New GH deficiency appeared in 39.0% (n = 16/41) of the
41 patients with normal GH function pre-operatively.
Figure 1 shows the incidence of new onset anterior pitu-
itary hormone dysfunction for each individual axis.
Pituitary axis recovery was noted in 20.8% of patients
(16/77 patients, excluding 24 patients who had normal
baseline pituitary function pre-operatively). Figure 2
shows the rate of recovery in each individual pituitary
axis after TSS. The highest rate of recovery was noted in
the HPA axis, where 7/33 (21.2%) with impairment of
the axis pre-operatively recovered normal function.
Volumetric analysis and tumour resection
The median pre-operative tumour volume was 5.51 cm3
(IQR 3.52–9.48 cm3) and median post-operative residual
tumour volume was 0.92 cm3 (IQR 0.44–2.02 cm3). In the
151 patients with preoperative and postoperative MRI
studies available for volumetric analysis, the median extent
of resection (EOR) was 82.3%, (IQR 64.8–91.5%). Table 3
shows the EOR achieved in the study population.
Table 1 Characteristics and post-operative outcomes of surgical naïve patients (Group A) undergoing endoscopic TSS (Continued)
Characteristics Values




Median tumour volume (cm3) At diagnosis (n=
156)
Post-operative (n=151)
5.51 IQR: 3.52 –
9.48
0.92 IQR: 0.44 – 2.02
Extent of tumour resection (EOR), median (%), n=151 82.3%, IQR: 64.8 – 91.5%
Gross Total Resection (GTR) 9 (6.0%)
Near-Total Resection (≥90%) 44 (29.1%), including 9 GTR
Subtotal Resection (75-89.9%) 53 (35.1%)
Partial Resection (<75%) 54 (35.8%)
Long-term follow-up
Mean Follow-up (years) 3.1 ± 2.1 years; Range 0.5-9.6 years
Large tumour remnant, requiring intervention 14 (8.8%)
Tumour regrowth 28 (17.6%), of which 24 (15.1%) required
intervention
Further Treatment
• Radiotherapy (RT) 35 (22.0%)
External beam RT: 25 (15.7%)
Stereotactic radiosurgery: 10 (6.3%)
• Repeat Surgery 9 (5.7%)
Deaths 11 (6.9%)
aincluding only patients with complete formal pre- and post-operative endocrine assessments (i.e. excluding 48 patients without dynamic GH stimulation tests at
baseline and/or after surgery and 10 additional patients with other missing endocrine data)
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Tumour size and pituitary function
The preoperative tumour volume did not correlate with
either gender (8.88 vs. 6.46 cm3, p = 0.12) or age at the
time of surgery (p = 0.35). Preoperative tumour size also
did not predict the severity of hypopituitarism (number of
axes affected) at diagnosis (6.28 vs. 9.00 vs. 7.92 cm3, p =
0.69). Individual pituitary hormone axis deficiencies at
diagnosis were independent of tumour size as shown in
Table 3. Likewise, in a multilinear regression, the absolute
postoperative volume of residuum did not predict the de-
gree of pituitary dysfunction postoperatively (p = 0.44).
Most importantly, the EOR (both percentage and absolute
volume reduction) during TSS was independent of the
new onset of pituitary hormone deficiencies postopera-
tively (78.6 ± 23.5 vs. 75.0 ± 21.2 cm3, p = 0.48). Similarly,
EOR was also not associated with recovery of pituitary
function after surgery (79.9 ± 16.9 vs. 75.2 ± 22.6 cm3, p =
0.45). The results are summarised in Table 3.
Fig. 1 Incidence of new onset pituitary hormone axis deficiency after TSS. For each hormone axis, the first bar denotes the number of patients
with normal function at baseline and the second bar denotes the percentage of these patients who developed hormonal deficit after TSS. GH
axis was the mostly affected post-operatively (39%) followed by ACTH deficiency (14.7%)
Table 2 Pituitary hormone function at baseline in the study population (n = 101) and association with different parameters
Number of pituitary hormone deficiencies (at baseline) Gender p-value
Males (n = 62) Females (n = 39)
• 0 12 (19.4%) 12 (41.6%) 0.06
• 1–2 24 (38.7%) 17 (43.5%)
• ≥3 26 (41.9%) 10 (25.6%)
Individual hormone axis
• GH deficiency 43 (63.4%) 17 (43.5%) 0.01*
• LH/FSH deficiency 37 (59.7%) 18 (21.2%) 0.22
• ACTH deficiency 22 (35.3%) 11 (28.2%) 0.52
• TSH deficiency 24 (38.7%) 12 (30.8%) 0.52
Number of pituitary hormone deficiencies (at baseline) Age at Surgery (mean ± SD)/ years p-value
• 0 54.7 ± 13.0 0.001*
• 1–2 57.7 ± 12.0
• ≥3 63.8 ± 11.6
Individual hormone axis Age at Surgery (mean ± SD)/ years p-value
• GH deficiency 60.6 ± 11.6 0.16
• LH/FSH deficiency 63.5 ± 11.0 < 0.01*
• ACTH deficiency 63.2 ± 13.2 0.03*
• TSH deficiency 62.2 ± 12.0 0.06
*p < 0.05 is statistically significant
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Fig. 2 Recovery of pituitary hormone dysfunction after TSS. For each hormonal axis, the first bar denotes the number of patients with that
particular hormone deficit at baseline and the second bar shows the proportion of patients who recovered normal function in that axis. The HPA
axis showed highest recovery post-operatively at 21.2% followed by GH (8.3%), LH/FSH (5.5%) and TSH (2.8%) respectively
Table 3 Tumour size and the impact on endocrine function in the study population (n = 101) at baseline and after TSS
Preoperative tumour volume Males (n = 62) Females (n = 39) p-value
Mean tumour size (cm3) ± SD 8.88 ± 8.56 6.46 ± 5.05 0.12
Age at surgery (years) 59.3 ± 13.3 0.35
Individual hormone axis Mean tumour size (cm3) p-value
• GH deficiency 8.45 ± 6.10 0.44
• LH/FSH deficiency 8.81 ± 8.92 0.22
• ACTH deficiency 7.17 ± 5.34 0.45
• TSH deficiency 7.88 ± 6.41 0.93
Number of pituitary hormone deficiencies
• 0 6.28 ± 4.18 0.69
• 1–2 9.00 ± 9.88
• ≥3 7.92 ± 5.91
Postoperative Tumour Residuum
Mean tumour residuum size (cm3) ± SD 1.96 ± 4.46
Number of pituitary hormone deficiencies Mean tumour size (cm3) p-value
• 0 1.68 ± 2.29 0.44
• 1–2 2.34 ± 6.39
• ≥ 3 1.24 ± 2.07
Extent of Resection (EOR)
Mean EOR (%) ± SD 75.9 ± 21.8; Range: 3.4–100%
Gross total resection (GTR) 7 (6.9%)
Near total resection (≥90 % ) 28 (27.7%), including 7 GTR
Subtotal resection (75–89.9%) 39 (38.6%)
Partial resection (< 75%) 30 (29.7%)
Endocrine outcomes Mean EOR (%) ± SD p-value
• New axis deficit (n = 25) 78.6 ± 23.5 0.48
• Axis recovery (n = 16) 79.9 ± 16.9 0.45
• Pituitary function preserved (n = 60) 73.8 ± 22.1 0.38
The effects of the extent of tumour resection are studied on the appearance of new hormone deficits and on axis recovery. A p-value of < 0.05 is considered
statistically significant
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Tumour size and further intervention
Table 1 shows the long-term outcomes in the study
population at the end of follow-up. After a mean follow-
up of 3.1 ± 2.1 years, 38 patients (23.9%) required further
intervention (radiation and/ or repeat surgery). 24
(15.1%) of these patients had demonstrated tumour re-
growth of the adenoma; the remainder 14 patients had a
significant tumour remnant with suprasellar extension
visible on scan postoperatively and were empirically
treated. Nine patients (5.7%) went on to have repeat sur-
gery. The indication for repeat TSS was tumour re-
growth causing visual field loss or threatening sight in
eight patients (8/9, 89%). In the remaining patient, the
decision for repeat debulking surgery was due to re-
growth in a sizeable tumour residuum in a young adult.
The mean interval between primary and repeat surgery
was 2.4 ± 1.2 years (range: 0.3–4.2 years). Thirty-five
(22.0%) patients were submitted to adjuvant radiother-
apy (RT), of whom 25 received conventional fractionated
external beam irradiation and 10 received stereotactic
gamma knife radiosurgery (SRS). Six patients required
both repeat surgery followed by adjuvant radiotherapy.
During a mean follow-up of 3.1 years, 28 patients dem-
onstrated a degree of tumour regrowth, including 24
who required further intervention and another 4 who
were not subject to secondary treatment during the
study period. When analysed by residual tumour vol-
ume, it was clear that a larger residuum significantly in-
creased the risk of tumour regrowth during
neurosurveillance imaging. This is illustrated in Fig. 3.
A larger residual tumour volume increased the likeli-
hood of further intervention (repeat TSS or RT, n = 38)
during follow-up (3.88 ± 6.82 vs. 1.24 ± 1.62 cm3, p <
0.001). When analysed separately, a large residual
tumour volume was predictive of adjuvant radiotherapy
(3.40 vs. 1.24 cm3, p = 0.005) as well as likelihood for
repeat surgery (5.40 vs. 1.67cm3, p = 0.004) during
follow-up. Gross total resection was achieved in 9 pa-
tients, only 1 of whom developed tumour recurrence
20.5 months after TSS. In addition, presence of a large
tumour volume at baseline was also predictive of further
intervention (repeat TSS or RT) during follow-up
(11.52 ± 11.03 vs. 6.48 ± 4.91 cm3, p = 0.001), irrespective
of EOR.
Operative experience and tumour resection (Group A)
Between 2009 and 2013, 48 NFPMA were resected by
TSS at our institution whilst 111 tumours were debulked
during the following 5-year period from 2014 to 2018.
The median EOR was 78.3% (IQR 63.5–84.2%) during
the first-half of the study period compared with 86.4%
(IQR 70.4–93.8%, p = 0.005) in the latter half. Despite a
net improvement in EOR during the latter 5 years most
likely related to improved surgical technique and experi-
ence, the incidence of new post-operative pituitary axis
dysfunction was not significantly different between the
two groups (23.5 vs. 25.4%, p = 0.99). Analysing both
study periods separately, it transpired that the onset of
new endocrine deficits after TSS was independent of the
EOR in each cohort (first half: 2009–2013, median EOR
82.7 vs. 76.2%, p = 0.15; second half: 2014–2018, median
EOR 82.9 vs. 83.9%, p = 0.36), highlighting that endo-
crine outcomes are independent of EOR. The results are
illustrated in Table 4.
Previous surgery cohort (Group B)
Our cohort included 23 patients (16 males; 57.0 ± 12.9
years) who underwent endoscopic TSS having had prior
pituitary surgery by microscopic TSS or transcranial
route (n = 14) or endoscopic TSS (n = 9). One patient
had undergone radiotherapy after the first surgery. Com-
paring patients who had primary surgery (microscopic
Fig. 3 Kaplan-Meier regrowth-free survival curves for total cohort of patients stratified by size of residual tumour volume (cm3). A larger residual
tumour volume increased the probability of tumour regrowth during follow-up (p = 0.03)
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TSS or transcranial surgery) before the implementation
of the endoscopic TSS technique with those who had
prior endoscopic TSS surgery, there was no significant
difference in EOR rates (median EOR 66.5% vs. 77.1%,
p = 0.20) after repeat surgery. Unfortunately, we did not
have tumour volume data to compute EOR rates on the
initial surgery undergone by the 14 patients prior to
endoscopic TSS.
On the other hand, although the mean preoperative
tumour volume did not significantly differ between pa-
tients who had prior surgical intervention before the
study period when compared to those who were
surgery-naïve, having had previous surgery was predict-
ive of decreased EOR (68.9% [IQR 42.4–80.2%] vs. 82.3%
[IQR 64.8–91.5], p = 0.017).
Discussion
We performed a cross-sectional study of consecutive
NFPMA treated surgically since adoption of endoscopic
transsphenoidal surgery in 2009 at our institution. Com-
prehensive clinical characterisation was undertaken of
endocrine status, pre- and post-operative tumour vol-
umes, and the requirement for further interventions.
The most important finding from these data is that pre-
and post-operative volumes, as well as EOR did not cor-
relate with the prevalence of pituitary hormone deficits,
however, the post-operative residual volume was predict-
ive of requirement for further intervention to control
the tumour mass. To our knowledge this is the first de-
scription of the impact of pituitary tumour volumes and
EOR on both endocrine status and the need for further
intervention for the tumour. In support of the dissoci-
ation between EOR / post-operative tumour volumes
and endocrine status, greater EOR was achieved in the
latter half of the study period, however, without change
in endocrine outcomes. Arguably, this could also be the
result of improved surgical experience, resulting in more
accurate resection margins with better visualisation,
without further compromise to endocrine function.
Interestingly, but not unexpectedly we also showed that
in patients who required second surgery the EOR was
significantly lower compared with surgical naïve
subjects.
In addition to symptoms from mass effect, NFPMA
are associated with a variable degree of hypopituitarism
in the majority of cases at presentation [6, 7, 17]. In
keeping with previously described cohorts of NFPMA, at
presentation our cohort showed hypopituitarism in
76.2% [6, 7, 17, 18], with the GH and Gn axes being
most frequently impaired [6, 7, 17, 19], and a greater
prevalence in those presenting at an older age [19–21].
We could find no correlation between pre-operative ad-
enoma volume and the presence of pituitary hormone
deficits. Previous reports have been inconsistent, with re-
ports of no relationship between pre-operative adenoma
volume and pituitary hormone deficits [21–23] and
other studies showing larger tumours to have a higher
prevalence of deficits [19, 24]. Differences likely relate to
heterogeneity of the cohorts studied in relation to
tumour size and rigour of endocrine testing. A number
of studies have included both micro and macroadeno-
mas [24], albeit microadenomas are infrequently associ-
ated with hormone deficits thereby potentially
explaining the finding of higher prevalence of pituitary
deficits with increasing tumour size. In contrast our
study included only macroadenomas. Furthermore, other
studies have not evaluated pituitary function with stimu-
lation tests, relying simply on basal hormone levels [19].
In our sub-cohort in which we present endocrine out-
comes we have fully characterized endocrine status in-
cluding stimulation tests to determine GH and cortisol
status pre- and post-operatively.
In the absence of proven medical therapies that can
reliably reduce NFPMA tumour mass, initial manage-
ment is limited to clinical assessment and neurosurveil-
lance with MRI scanning, or surgical resection of the
tumour. Previously published data suggest tumour re-
growth rates of 15–50% within 5 years after surgery
Table 4 Comparison of parameters between the first and second half of the study period
Characteristic Study period p-
value2009–2013 2014–2018
Patients (n = 159) 48 111
Preoperative tumour volume (median, cm3) 5.51 (IQR: 2.84–9.56) 5.51 (IQR: 3.56–9.27) 0.75
Postoperative residual tumour volume (median, cm3) 1.28 (IQR: 0.61–2.19) 0.77 (IQR: 0.39–1.72) 0.01*
EOR (median, %) 78.3 (IQR: 63.5–84.2) 86.4 (IQR: 70.4–93.8) 0.005**
Endocrine Outcomes (n = 101)a
• Preserved function 23/34 (67.6%) 37/67 (56.7%) 0.29
• New hormone deficit(s) 8/34 (23.5%) 17/67 (25.4%) 0.99
• Axis recovery 3/34 (8.8%) 13/67 (19.4%) 0.25
aComplete endocrine data pre- and post-TSS was available in 101 patients (34 of whom were in the first half, 2009–2013 and 67 in the second half, 2014–2018)
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alone [25, 26]; size of the post-operative tumour
remnant being a major determinant of regrowth [25].
Without adjuvant treatment, regrowth rates of 50–60%
were observed after subtotal resection and upwards of
20% after gross total resection with increased length of
follow-up [26, 27]. Five-year regrowth rates reduce to 2–28%
after surgery followed by adjuvant radiotherapy [25–28].
Neurosurgical guidelines recommend resection of
symptomatic NFPMA as first-line treatment [29] in
symptomatic NFPMA with the aim of relieving symp-
toms caused by mass effect; with emphasis on decom-
pression of the optic nerve to preserve or improve
vision, but also to reduce headaches, and prevent further
deterioration of endocrine function as a secondary out-
come. However, preservation and restoration of hormo-
nal function are also essential to assessing the outcome
of surgery and to the patient’s quality of life. In this set-
ting, ACTH and gonadotropin deficiencies have been as-
sociated with increased mortality risk in a large cohort
of NFPA patients [30]. Surgical intervention can be ef-
fective in normalising pituitary function with a variable
reported improvement in degree of hypopituitarism ran-
ging from 2 to 49% [10, 31–33]. Pituitary function was
preserved in 59% of our patients, whilst there was an im-
provement in pituitary dysfunction in 21% of patients
post-operatively. In our study, and as reported by others
[8, 34], ACTH was the most frequent axis to show re-
covery in our study. Resection of the pituitary adenoma
reduces intrasellar pressure, providing a mechanism by
which pituitary hormone recovery can occur post-
operatively [22]. However, chronically elevated intrasel-
lar pressure may lead to ischaemic necrosis of anterior
pituitary cells and limited potential to regenerate leading
to permanent hypopituitarism.
In our cohort, development of new pituitary hormone
deficiencies was independent of initial tumour size, post-
operative tumour volume and extent of tumour resec-
tion. Our findings are consistent with those of Jahangiri
et al. (2016) who also pointed out that preoperative
tumour size, postoperative tumour size and extent of re-
section did not predict development of new postopera-
tive endocrine deficits [20]. A further study showed that
although pituitary tumour size did not correlate with post-
operative recovery of hypopituitarism [12], absence of
tumour residuum on postoperative pituitary imaging cor-
related with a higher chance of postoperative pituitary
function recovery in a mixed cohort of non-functioning
and hypersecreting pituitary adenomas. In contrast to
these studies others have shown preoperative tumour size
to relate to postoperative hormonal deficits [21].
Finally, in our study the presence of a large tumour
residuum was predictive of likelihood of further inter-
vention, with adjuvant radiotherapy and/or repeat sur-
gery. This finding is in agreement with the majority of
the literature which shows that the volume of postopera-
tive tumour remnant predicts recurrence / progression
of the tumour [6, 7, 18, 35], in particular a postoperative
tumour remnant with extrasellar component [25]. Post-
operative residuum is not unique as a predictor of recur-
rence / progression, with a number of additional factors
being important in this including age, invasiveness, pro-
liferative character of the tumour, and duration of
follow-up [35]. Preoperative size has also been observed
to correlate with the need for further intervention [36],
as evident in our study. Many of these variables are not
mutually exclusive as larger tumours preoperatively are
more likely to be invasive, and lead to a larger postoper-
ative residuum. The EOR is another crucial parameter in
transsphenoidal pituitary surgery and is linked to post-
operative morbidity and mortality [37]. In our study, a
lower rate of EOR was predictive of adjuvant radiother-
apy or repeat TSS during follow-up. Maximising EOR is
thus of particular relevance; however several factors, in-
cluding invasion into the cavernous sinus, graded with
the Knosp scale as well as the pituitary adenoma volume,
influence the likelihood of achieving gross total resection
rates [37]. In our study, insufficient information on the
Knosp grade did not allow a robust explanation as to the
GTR observed, although a negative association was dem-
onstrated between preoperative tumour size and EOR.
The limitations of our study are its retrospective, non-
randomized nature in a single tertiary referral centre,
making it susceptible to selection bias for the management
approaches during follow-up, although a prospective study
would not be feasible in this setting. In addition, improved
surgical technique and experience in endoscopic TSS over
the 10 years (2009–2018) could also explain the improved
EOR and preserved/ improved endocrine function noted
in the latter part of the study period. Despite a relatively
shorter follow-up, our findings are however comparable to
longitudinal studies in other centres. Data from other UK
series suggest 5-year tumour regrowth rates of 23–34%
after surgery alone [25, 37] whilst we demonstrated a 18%
relapse after a mean follow-up of 3 years. The advantages
are a large cohort of nonselected subjects with non-
functioning pituitary macroadenomas, reliable endocrine
assessments by pituitary stimulation tests and accurate
tumour volume measurements before and after surgery.
Importantly our data have shown dissociation between
the endocrine and tumoral outcomes when related to
adenoma size; tumour size being less important to endo-
crine outcomes than to the need for further intervention.
This dissociation is further exemplified in our data by
examining the cohort after stratification in to the first
five, and second 5 years of surgical experience. These
data showed increased EOR, and thus reduced risk of re-
currence / progression, without significant adverse endo-
crine outcomes.
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Conclusions
In a large cohort of patients with NFPMA we have
shown pre- and post-operative tumour volumes, as well
as EOR do not correlate with the prevalence of pituitary
hormone deficits, however, the post-operative residual
volume is predictive of the requirement for further inter-
vention to control the tumour mass. In the hands of an
experienced neurosurgeon, total/ subtotal resection of
pituitary adenoma is not a significant risk to pituitary
function but may be protective of future invasive inter-
vention, including radiotherapy and repeat surgery
which have their own complications and risks to pituit-
ary function.
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